No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HUMA240517C7500
- 0.10
- +0.09+900.00%
15min DelayClose May 13 15:59 ET
0.10High0.02Low
0.02Open0.01Pre Close226 Volume1.26K Open Interest7.50Strike Price1.11KTurnover246.69%IV38.69%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type0.1485Delta0.1587Gamma54.80Leverage Ratio-0.0386Theta0.0001Rho8.14Eff Leverage0.0014Vega
Intraday
- 5D
- 1D
News
10-Q: Quarterly report
Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Rallybio (RLYB)
Express News | Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Humacyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 215.79% Benchmark → $15 Reiterates Buy → Buy 04/01/2024 47.37% Cantor Fitzgerald → $7 Reiterate
Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)
Humacyte Inc (HUMA) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
Comments
$Humacyte(HUMA.US$ Senator Tommy Tuberville filed 8 security purchases, including small biotech company Humacyte (HUMA) which has been testing to repair injuries in Ukraine.
1
2
$Humacyte(HUMA.US$ Humacyte Announces FDA Has Accepted And Granted For Priority Review The Company's Biologics License Application Seeking Approval Of Human Acellular Vessel
Read more
Dream is Possible : What would have happened if Ukraine surrendered ealier